• / Free eNewsletters & Magazine
  • / My Account
Home>GlaxoSmithKline Announces Positive Results for Triple-Therapy Inhaler

GlaxoSmithKline Announces Positive Results for Triple-Therapy Inhaler

GlaxoSmithKline Announces Positive Results for Triple-Therapy Inhaler

09/20/2017

 By Oliver Griffin 

GlaxoSmithKline PLC (GSK.LN) and Innoviva Inc. (INVA) on Wednesday reported positive headline results from a phase-three impact study of Trelegy Ellipta, a triple-therapy inhaler for patients with chronic obstructive pulmonary disease.

The Trelegy Ellipta is approved by the U.S. Food and Drug Administration and designed to be used once daily for long-term maintenance treatment.

GlaxoSmithKline said the Trelegy Ellipta study, which involved 10,355 patients, showed significant reductions in the annual rate of on-treatment exacerbations when compared with the dual-therapy treatments it has in its portfolio.

 

Write to Oliver Griffin at oliver.griffin@dowjones.com

 

(END) Dow Jones Newswires

September 20, 2017 03:00 ET (07:00 GMT)

Copyright (c) 2017 Dow Jones & Company, Inc.

1

©2017 Morningstar Advisor. All right reserved.